Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 9/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169187 | 0.97 | AGTR1 (0.52) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL7668569 | 0.94 | TDP1 (0.52) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL7671157 | 0.92 | NPSR1 (0.53) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL7676640 | 0.90 | PDE2A (0.53) | KDM4EALDH1A1LMNAHPGDNPSR1 | |
| SCHEMBL7676515 | 0.90 | PPARG (0.55) | ALDH1A1LMNASMN1; SMN2AGTR1AGTR2 | |
| SCHEMBL7671741 | 0.89 | AGTR1 (0.61) | AGTR1AGTR2PDE2A | |
| SCHEMBL6170161 | 0.88 | AGTR1 (0.66) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL7670036 | 0.87 | AGTR1 (0.57) | KDM4EALDH1A1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL6168511 | 0.86 | ALOX5AP (0.51) | KDM4EALDH1A1LMNASMN1; SMN2NPSR1 | |
| SCHEMBL6173569 | 0.86 | MAPT (0.52) | KDM4EALDH1A1LMNASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | CAMPBELL SIMON FRASER (GB) | 2001-11-22 | — | — | US | claimed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
| JP-5222000-A | — | — | None | — | — | JP | disclosed |
| US-20150250801-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | BESINS HEALTHCARE LUXEMBOURG SARL (LU) | 2015-09-10 | — | — | US | disclosed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| US-20140142077-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | LABORATORIES BESINS INTERNATIONAL, SAS (FR) | 2014-05-22 | — | — | US | disclosed |
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120245134-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-09-27 | — | — | US | disclosed |
| US-8263555-B2 | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-09-11 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| US-6156753-A | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| US-6127363-A | FOR TRANSURETHRAL OR TRANSDERMAL ADMINISTRATION OR INTRACAVERNOSAL INJECTION, KITS | VIVUS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | disclosed |
| JP-H05222000-A | BENZIMIDAZOL DERIVATIVE AND PRODUCTION THEREOF | FUJISAWA PHARMACEUT CO LTD | 1993-08-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | KDM4E 3092/4885ALDH1A1 3886/4885LMNA 1161/4885 |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE2A | KDM4E 892/4885ALDH1A1 412/4885LMNA 2354/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | KDM4E 3682/4885ALDH1A1 4758/4885LMNA 1476/4885 |
| US-20010044441-A1 | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE2A, PDE3B | KDM4E 850/4885ALDH1A1 565/4885LMNA 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.